Khiron Life Sciences Corp.
KHRNF · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $4 | $5 | $4 |
| % Growth | -24.3% | -3.7% | 27.7% | – |
| Cost of Goods Sold | $2 | $2 | $3 | $2 |
| Gross Profit | $2 | $2 | $1 | $1 |
| % Margin | 48.8% | 52.6% | 32.2% | 32.2% |
| R&D Expenses | $0 | $1 | $1 | $0 |
| G&A Expenses | $4 | $3 | $5 | $5 |
| SG&A Expenses | $5 | $4 | $6 | $6 |
| Sales & Mktg Exp. | $1 | $1 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $5 | $5 | $7 | $6 |
| Operating Income | -$3 | -$3 | -$5 | -$3 |
| % Margin | -101.7% | -70.9% | -103.9% | -85.5% |
| Other Income/Exp. Net | $0 | $1 | -$0 | -$15 |
| Pre-Tax Income | -$3 | -$2 | -$5 | -$20 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$4 | -$2 | -$5 | -$20 |
| % Margin | -105.6% | -48.5% | -116.6% | -536.3% |
| EPS | -0.017 | -0.012 | -0.03 | -0.11 |
| % Growth | -44% | 61.6% | 72.5% | – |
| EPS Diluted | -0.017 | -0.012 | -0.03 | -0.11 |
| Weighted Avg Shares Out | 215 | 186 | 179 | 179 |
| Weighted Avg Shares Out Dil | 215 | 186 | 179 | 179 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$3 | -$3 | -$5 | -$3 |
| % Margin | -85.3% | -56.3% | -99.3% | -81.4% |